Back to Treatments
Oncology

Cancer Immunotherapy (PD-1/PD-L1)

肿瘤免疫治疗

Duration

6-12 months (every 2-3 weeks)

Recovery

1-3 days per cycle

$

Savings

~70% vs US

Price Comparison
China$3,000 - $8,000
$5,500
United States$12,000 - $25,000
$18,500
Save approximately 70%

Average savings compared to US prices

About This Treatment

China has developed multiple PD-1 inhibitors including sintilimab (Innovent), tislelizumab (BeiGene), camrelizumab (Hengrui), and toripalimab (Junshi) at a fraction of US pricing. These domestically-developed drugs have been validated in major clinical trials and approved for lung, liver, gastric, and esophageal cancers. With 60-75% cost savings per cycle compared to pembrolizumab or nivolumab in the US, China offers world-class immunotherapy backed by extensive real-world treatment data.

Procedure Steps
1

Biomarker Testing

Comprehensive genomic profiling including PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) status to predict treatment response.

Duration: 5-7 days
2

Treatment Plan Design

Oncology team designs personalized immunotherapy protocol, selecting optimal drug and combination strategy based on cancer type and biomarker results.

Duration: 3-5 days
3

Infusion Sessions

Intravenous immunotherapy infusions administered every 2-3 weeks in outpatient oncology centers with monitoring for infusion reactions.

Duration: 1-2 hours per session
4

Response Assessment Imaging

Regular CT/MRI scans every 6-8 weeks to evaluate tumor response using iRECIST criteria, with treatment continuation or modification based on results.

Duration: 1-2 days
Benefits
  • 60-75% cost savings with domestically developed PD-1 inhibitors
  • Wide cancer coverage including lung, liver, gastric, and esophageal cancers
  • Can be combined with chemotherapy for enhanced efficacy
  • Extensive real-world data from large Chinese patient populations
Considerations
  • Immune-related adverse events affecting thyroid, liver, lungs, or skin
  • Not all patients respond to immunotherapy (30-40% response rate varies by cancer)
  • Requires regular monitoring with blood tests and imaging
  • Potential for severe autoimmune reactions requiring treatment discontinuation

Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.